Abstract: The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody and pembrolizumab.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: An electrical charging system configured to charge a battery includes a power transmitter, an energy coupling arrangement, an electrical signal shaping device including a controller, and an alignment means. The arrangement includes a first inductive coil disposed external to the vehicle and a second inductive coil attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second inductive coil is positioned relative to the first inductive coil so that the second inductive coil receives the energy produced by the power transmitter wirelessly transmitted from the first inductive coil. The energy received by the second inductive coil is electrically shaped by the electrical signal shaping device and further transmitted through the electrical signal shaping device as controlled by the controller to charge the battery. Methods for transmitting energy through the electrical charging system to charge the battery are also presented.

Abstract: An electrical charging system configured to charge a battery includes a power transmitter, an energy coupling arrangement, an electrical signal shaping device including a controller, and an alignment means. The arrangement includes a first inductive coil disposed external to the vehicle and a second inductive coil attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second inductive coil is positioned relative to the first inductive coil so that the second inductive coil receives the energy produced by the power transmitter wirelessly transmitted from the first inductive coil. The energy received by the second inductive coil is electrically shaped by the electrical signal shaping device and further transmitted through the electrical signal shaping device as controlled by the controller to charge the battery. Methods for transmitting energy through the electrical charging system to charge the battery are also presented.

Abstract: A wireless vehicle battery charging system includes an off-vehicle transducer connected to a power source and configured to wirelessly transmit and receive a first alternating current having a first frequency, an on-vehicle transducer configured to wirelessly transmit and receive the first alternating current, and a frequency converting circuit connected to the on-vehicle transducer. The frequency converting circuit is configured to change the first frequency of the first alternating current to a second alternating current having a second frequency. The system further includes a battery within the vehicle and a regenerative braking circuit connected to the frequency converting circuit and the battery. The regenerative braking circuit is configured to rectify the second alternating current to a direct current supplied to the battery and configured to convert the direct current from the battery to the second alternating current supplied to the frequency converting circuit.

Abstract: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling.

Abstract: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method that facilitates complying with traffic restrictions that involve three or more connected road segments when using a navigation system to determine a route. The method includes forming multiple instances of data representing each intermediate road segment between an entrance segment and an exit segment and storing data defining restrictions that apply to only two connected road segments, such that a valid driving paths exists between the entrance segment and the intermediate segment and between the intermediate segment and the exit segment, but that no valid driving paths exist between the entrance segment and the exit segment.